NBE Therapeutics
Cornelia Baumgartner- Diolaiuti has worked in various roles in the clinical operations field since 2000. Cornelia started as a Clinical Research Associate at Pfizer in 2000, then moved to Clinical Research Manager at Straumann TR in 2003. In 2014, they became a Clinical Research Associate at Universitätsspital Basel. From 2015 to 2018, they worked at Aridis Pharmaceuticals as a Clinical Operations Manager and Associate Director Clinical Operations. In 2018, they became a Sr. Manager Clinical Operations at Mundipharma. In 2020, they took on roles as Clinical Project Lead at Novimmune and Clinical Operations Manager at NBE-Therapeutics AG.
Cornelia Baumgartner-Diolaiuti completed their Diplom in Examinierte Krankenschwester/Examinierter Krankenpfleger from Theodosianum Schule für Gesundheits und Krankenpflege. In 2010, they obtained a Diploma of Advanced Studies Clinical Trial Practice and Management from the Medical Faculty of the University of Basel. Cornelia then went on to complete a Diploma of Advanced Studies in Clinical Trial Practice and Management from the University of Basel in 2012.
This person is not in any offices
NBE Therapeutics
1 followers
NBE-Therapeutics is developing best-in-class cancer therapies to increase survival and improve quality of life for cancer patients worldwide. The company’s next-generation immune-stimulatory therapies are based on a proprietary, highly differentiated Antibody-Drug Conjugate (ADC) platform. This best-in-class ADC platform creates highly potent and safe immune-stimulatory ADCs ("iADCs™") with an anthracycline payload, not only directly targeting tumor cells, but also inducing a long-lasting immunological anti-tumor effect. The company’s lead asset, NBE-002, an anti-ROR1 ADC, is due to start first-in-human clinical trials in three US centers by the end of 2020, focusing on triple negative breast cancer, but also other solid cancer indications which express ROR1. NBE-Therapeutics is a privately owned biotech company based in Basel, financed by Germany’s Boehringer Ingelheim Venture Fund, the Czech Republic’s PPF Group and Denmark’s Novo Holdings as international institutional investors, and by Swiss, German, and Dutch private investors. The company has raised over USD 65m, including a USD 22m Series C (2020), two USD 20m Series B rounds (2016 & 2018), a USD 3m Series A (2015), and over USD 4m from several non-dilutive grants from organizations including the Swiss Commission for Technology & Innovation, the European Commission, and Systems-X.